US FDA strengthens warnings on Glaxo, Roche/Biogen cancer drugs

World News
25-09-2013 | 11:39
High views
Share
LBCI
Share
LBCI
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
US FDA strengthens warnings on Glaxo, Roche/Biogen cancer drugs
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
0min
US FDA strengthens warnings on Glaxo, Roche/Biogen cancer drugs

U.S. regulators strengthened the warning labels on two cancer drugs - GlaxoSmithKline Plc's  Arzerra, and Rituxan, made by Biogen Idec Inc and Roche Holding AG - to reflect the risk that they can reactivate the hepatitis B virus in patients previously infected with it.          

The U.S. Food and Drug Administration said the risk is already described in the warnings and precautions section of the label for both drugs. Now the information will be placed in a black box, indicating the most serious type of risk.               


REUTERS
Download now the LBCI mobile app
To see the latest news, the latest daily programs in Lebanon and the world
Google Play
App Store
We use
cookies
We use cookies to make
your experience on this
website better.
Accept
Learn More